Wiley Blackwell

SHERPA: Unknown

People

  1. Weigelt
    Weigelt
  2. Horwitz
    Horwitz
  3. Yahalom
    Yahalom
  4. Coleman
    Coleman
  5. Hakimi
    Hakimi
  6. Marghoob
    Marghoob
  7. Ganly
    Ganly
  8. Geller
    Geller
  9. Moskowitz
    Moskowitz
  10. Dogan
    Dogan

Groups

  1. Sloan Kettering Institute Postdocs (426)
  2. Department of Medicine (141)
  3. GSK Faculty (133)
  4. Surgery (103)
  5. Survivorship Research (101)
  6. Department of Pathology and Laboratory Medicine (89)
  7. Solid Tumor Oncology Division (71)
  8. Sloan Kettering Institute Faculty (64)
  9. Radiology, Department of (55)
  10. Center for Hematologic Malignancies (53)
Search Within
  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (282)
  2. Meeting Abstract (81)
  3. Review (35)
  4. Research Letter (10)
  5. Book Section (6)
  6. Editorial (5)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Book Whole (1)
  10. Conference Paper (1)
  11. Miscellaneous (1)
Groups
  1. Sloan Kettering Institute Postdocs (426)
  2. Department of Medicine (141)
  3. GSK Faculty (133)
  4. Surgery (103)
  5. Survivorship Research (101)
  6. Department of Pathology and Laboratory Medicine (89)

More Groups

People
  1. Britta Weigelt (28)
  2. Salvador Rodriguez (26)
  3. Jorge Reis-Filho (25)
  4. Katja Pinker-Domenig (21)
  5. Joachim Yahalom (16)
  6. Steven Horwitz (16)

More People

Years
  1. 2025 (11)
  2. 2024 (42)
  3. 2023 (44)
  4. 2022 (31)
  5. 2021 (37)
  6. 2020 (41)

More Years

Publications
  1. Journal of Surgical Oncology (36)
  2. Hematological Oncology (31)
  3. Cancer (29)
  4. Histopathology (28)
  5. Journal of Magnetic Resonance Imaging (27)
  6. Journal of the European Academy of Dermatology and Venereology (26)

More Publications

Results (426)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis
    Meeting Abstract

    Patel, A. R.; Limbrick‐Oldfield, E. H.; Kanters, S.; Ray, M. D.; Best, T.; Ghione, P.; Neelapu, S. S.; Gribben, J. G.; Beygi, S.; Bobillo, S.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)
    Meeting Abstract

    Freret, M. E.; Tringale, K. R.; Imber, B. S.; Joffe, E.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genomic correlates of radiosensitivity in diffuse large B cell lymphoma
    Meeting Abstract

    Sarkar, R. R.; Ma, J.; Wijetunga, N. A.; Salles, G.; Joffe, E.; Imber, B.; Yahalom, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies
    Meeting Abstract

    Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save